A Single Supratherapeutic Dose of Vorinostat Does Not Prolong the QTc Interval in Patients with Advanced Cancer

200948 citationsJournal Article

Authors

Pamela N. Münster · Moffitt Cancer Center

Eric H. Rubin · Moffitt Cancer Center

Simon Van Belle · Moffitt Cancer Center

Evan Friedman · Rutgers Cancer Institute of New Jersey

Jaclyn K. Patterson · Rutgers Cancer Institute of New Jersey

Kristien Van Dyck · Rutgers Cancer Institute of New Jersey

Xiadong Li

Abstract

Administration of a single supratherapeutic dose of the histone deacetylase inhibitor vorinostat is not associated with prolongation of the QTc interval. A dedicated QTc study in advanced cancer patients is a robust means for assessing risk for ventricular repolarization prolongation.

Topics & Keywords

Histone Deacetylase Inhibitors Research Peptidase Inhibition and Analysis

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: Clinical Cancer Research

Volume 15, Issue 22, pp. 7077-7084

DOI: 10.1158/1078-0432.ccr-09-1214

Field-Weighted Citation Impact: 2.76